All In Biotech

Drug Trial Radar · NCT05163028

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Dec 13, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
HUYABIO International, LLC.Industry
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.

Conditions

  • Non Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Solid Tumor
  • Cancer
  • Cancer of Pancreas
  • Cancer of Colon

Interventions

  • HBI-2376Drug

    SHP2 Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.Time frame: Up to 36 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • California Cancer Associates for Research and Excellence, Inc. (cCare)

    Encinitas, California

  • Providence Medical Foundation

    Fullerton, California

  • California Cancer Associates for Research and Excellence, Inc. (cCare)

    San Marcos, California

  • Sarcoma Oncology

    Santa Monica, California

  • UCLA Hematology/Oncology

    Santa Monica, California

  • Orlando Health, Inc.

    Orlando, Florida

  • BRCR Medical Center

    Plantation, Florida

  • Gabrail Cancer Center

    Canton, Ohio

  • Texas Oncology - Tyler

    Tyler, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Pan American Center for Oncology Trials (PanOncology Trials)

    Rio Piedras, Puerto Rico, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.